Form 4: Inovio Pharmaceuticals, Inc. (INO), Dansey Roger D, transaction 05/13/2021
Summary
Roger Dansey, a Director of INOVIO PHARMACEUTICALS, INC. [ INO ], reports two grants dated 05/13/2021 under the issuer's non-employee director compensation policy: Common Stock Options for 54,000 shares at $ 6.23, expiring 05/13/2031, and 36,000 Restricted Stock Units. The options vest 13,500 shares on May 13, 2021 and 13,500 on each of May 13, 2022, May 13, 2023 and May 13, 2024. The units vest 12,000 shares on May 13, 2022, May 13, 2023 and May 13, 2024, each unit a contingent right to one share of common stock. The form is signed /s/ Dansey Roger, 05/17/2021.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 4: Inovio Pharmaceuticals, Inc. (INO), Dansey Roger D, transaction 05/13/2021.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ino-4-filed2021-05-17-0001055726-21-000042-943ec3c0c1/
, SHA-256 0ab3e90271fd439f6e8eb98e74e295a0f1ca375691d7ff27f1ebbe072a9c9778.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * DANSEY ROGER D (Last) (First) (Middle) 660 W. GERMANTOWN PIKE SUITE 110 (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | DANSEY ROGER D | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE SUITE 110 | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 05/13/2021 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Common Stock Options | $ 6.23 | 05/13/2021 | A | 54,000 (1) | (2) | 05/13/2031 | Common Stock | 54,000 | $ 0 | 54,000 | D Restricted Stock Unit | (3) | 05/13/2021 | A | 36,000 (1) | (3) | (3) | Common Stock | 36,000 | $ 0 | 36,000 | D Explanation of Responses: 1. This grant was made pursuant to the issuer's non-employee director compensation policy. 2. The vesting schedule for the 54,000 options is as follows: 13,500 shares vested on May 13, 2021; 13,500 shares will vest on May 13, 2022; 13,500 shares will vest on May 13, 2023; 13,500 shares will vest on May 13, 2024. 3. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares will vest on May 13, 2022; 12,000 shares will vest on May 13, 2023; 12,000 shares will vest on May 13, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Remarks: /s/ Dansey Roger | 05/17/2021 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_INO_4_filed2021-05-17_0001055726-21-000042.xml
- Size
- 17,258 bytes
- SHA-256
- 0ab3e90271fd439f6e8eb98e74e295a0f1ca375691d7ff27f1ebbe072a9c9778
- Original
- www.sec.gov